Ffrdc PTH-1A drug product for pediatric dosing
Active Awarded Last action
- Contract number
- 75N91026F00022
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $559,073
Award facts
- Contract value 100% obligated
- $559,073.00 Current and potential, with all options
- Completion date 2% complete
- Current and potential, with all options
- Funding agency
- National Center for Advancing Translational Sciences National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this award
The National Center for Advancing Translational Sciences issued a delivery order to Leidos Biomedical Research Inc. on September 21, 2026, with a ceiling value of $559,073, under a cost-plus-fixed-fee pricing structure for pediatric dosing drug product development.
Place of performance is Frederick, MD. The order is scheduled for completion by September 20, 2030. Leidos Biomedical Research operates the Frederick National Laboratory for Cancer Research as an FFRDC contractor, delivering biomedical research and facilities support services to the National Institutes of Health. The company's work portfolio spans biomedical research execution, clinical trial support, specialized manufacturing including monoclonal antibodies and gene therapy vectors, and facilities infrastructure management across the Frederick campus and subordinate NIH institutes.
Quick answers
Who was awarded contract 75N91026F00022?
75N91026F00022 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 21, 2026.
How much is contract 75N91026F00022 worth?
The government has obligated $559,073 on 75N91026F00022.
Which agency awarded contract 75N91026F00022?
National Cancer Institute (National Institutes of Health) awarded 75N91026F00022, with funding from National Center for Advancing Translational Sciences (National Institutes of Health).
Is contract 75N91026F00022 an order under another contract?
Yes. 75N91026F00022 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91026F00022 competed?
The extent of competition for 75N91026F00022 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award